Sarepta Therapeutics’ shares plummeted over 30% as the FDA considers halting shipments of its gene therapy treatment, Elevidys, due to safety concerns. The therapy is linked to two patient deaths, raising doubts about its benefits for Duchenne Muscular Dystrophy. Investors fear FDA rejection could spell the end for Sarepta, whose stock has already fallen 87% this year.

Read more at CNBC: Sarepta stock falls on FDA gene therapy Elevidys comment